TORONTO, May 10, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. (“Transition” or the “Company”) (Nasdaq:TTHI) (TSX:TTH), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.
